The impact of immune system in regulating bone metastasis formation by osteotropic tumors by D\u27Amico, Lucia & Roato, Ilaria




The impact of immune system in regulating bone
metastasis formation by osteotropic tumors
Lucia D'Amico
Washington University School of Medicine in St. Louis
Ilaria Roato
University of Turin
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
D'Amico, Lucia and Roato, Ilaria, ,"The impact of immune system in regulating bone metastasis formation by osteotropic tumors."
Journal of Immunology Research.2015,. 1-8. (2015).
http://digitalcommons.wustl.edu/open_access_pubs/4176
Review Article
The Impact of Immune System in Regulating Bone Metastasis
Formation by Osteotropic Tumors
Lucia D’Amico1 and Ilaria Roato2
1Department of Orthopedics, Washington University School of Medicine, St. Louis, MO 63130, USA
2CeRMS, San Giovanni Battista General Hospital, University of Turin, Via Santena 5, 10126 Turin, Italy
Correspondence should be addressed to Ilaria Roato; roato78@libero.it
Received 13 October 2014; Accepted 2 December 2014
Academic Editor: Roberta Faccio
Copyright © 2015 L. D’Amico and I. Roato. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Bone metastases are frequent and debilitating consequence for many tumors, such as breast, lung, prostate, and kidney cancer.
Many studies report the importance of the immune system in the pathogenesis of bone metastasis. Indeed, bone and immune
system are strictly linked to each other because bone regulates the hematopoietic stem cells from which all cells of the immune
system derive, and many immunoregulatory cytokines influence the fate of bone cells. Furthermore, both cytokines and factors
produced by immune and bone cells promote the growth of tumor cells in bone, contributing to supporting the vicious cycle of
bone metastasis.This review summarizes the current knowledge on the interactions among bone, immune, and tumor cells aiming
to provide an overview of the osteoimmunology field in bone metastasis from solid tumors.
1. Introduction
The skeleton is the most common site of metastasis and
bone in turn is the main responsible of death since the
presence of bone metastases makes the primary disease no
longer curable [1]. Symptoms like bone pain, hypercalcemia,
fracture, and spinal cord compression appear in this type of
metastasis, causing a decline in the quality of life [2]. Some
types of tumors are characterized by a selective bone tropism,
out of which are prostate, breast, lung, and kidney cancers.
Bone metastases can give osteolytic, osteosclerotic, or mixed
lesions. Osteolytic metastases are due to an enhanced activity
of bone-resorbing cells, the osteoclasts (OCs), which cause
bone destruction [3, 4]. Typically, breast, lung, and kidney
cancers metastasize to bone with osteolytic lesions, whereas
prostate cancer metastasizes with osteosclerotic ones. Lung
and kidney tumors metastasize in an early phase of the
disease, while breast cancer metastasizes with a slower
and less aggressive growth. At least 65–75% of breast and
prostate cancer patients develop bone metastases during the
course of their disease, and breast cancer patients show
a relatively long median survival time after diagnosis of
bone metastases [5–7]. Bonemetastases from prostate cancer
are typically osteosclerotic and are caused by an increased
activity of bone-forming cells, the osteoblasts (OBs), leading
to enhanced bone formation [3, 4].
Approximately 30–40% of NSCLC patients develop bone
metastasis during their disease, with a median survival time
measured in months [1]. About 20–35% of kidney cancer
patients develop bone metastases, which are particularly
destructive, with a rate of skeletal complications higher
than other tumors [8, 9]. Accumulating evidences suggest
the importance of the immune cell response to factors in
the tumor microenvironment as main regulator of cancer
progression and metastases. The bone marrow is a reservoir
for immune cells such as macrophages, dendritic cells (DCs),
myeloid derived suppressor cells (MDSCs), and different T
cell subsets that can directly impair the so called “tumor/bone
vicious cycle” [10].This review focuses on the current knowl-
edge of the role of the immune cells in controlling tumor
spreading to bone.
2. Bone Marrow Is an Attractive Soil for
Cancer Cells
Bone marrow (BM) microenvironment is a fertile soil for
homing, survival, and proliferation of circulating cancer cells.
It provides both endosteal and vascular niches, which support
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Figure 1: Interactions among bone, immune, and tumor cells sustain the vicious cycle of bone metastasis. Tumor cells release cytokines
that activate T cells to produce proosteoclastogenic factors, such as RANKL, which activate OCs. In turn, the release of bone matrix growth
factors during bone resorption enhances the tumor growth. MDSCs originate from BM and migrate to secondary lymphoid organs where
they inhibit the antitumor immune response mediated by CD8 T cells. Consequently, the increased tumor growth induces the production of
osteolytic factors which activates the OCs, the cells responsible for bone destruction.
hematopoietic and nonhematopoietic stem cells such as mes-
enchymal stem cells [11]. OCs degrade endosteal components
and promote mobilization of hematopoietic progenitor cells
[12], whereas OBs on the endosteal surface of bone are
critical supporting cells for hematopoietic stem cells (HSCs)
in BM [13, 14]. Indeed, stimulation of the PTH (parathyroid
hormone) receptor on OBs increased the number of HSCs
in BM [13] and also the size of HSC niche, which promotes
skeletal localization of prostate cancer cells [15]. Shiozawa
et al. demonstrated that, after injection in a mouse model of
bone metastasis, human prostate cancer cells occupy mouse
HSC niche, displacing HSCs. Thus, the HSC niche is a direct
target of prostate cancer cells during dissemination and plays
a pivotal role in bonemetastases [16]. BM tissue is constituted
by red and yellow marrows. Red marrow contains HSCs and
yellow marrow mainly consists of fat cells [17]. Red marrow
is particularly vascularised; thus, it is a common site of
metastasis. Recently, an important role of yellow marrow in
the pathogenesis of bone metastasis has also been recognized
because bone marrow adipocytes promote the growth of
metastatic tumor cells in bone [18].
In physiological conditions, bone undergoes a constant
remodelling through OC-mediated bone resorption and
OB-mediated bone regeneration in a coupled manner to
maintain homeostasis. However, during tumor growth in
the bone, dysregulation of this process leads to osteolytic or
osteosclerotic phenotypes [19]. Indeed, cancer cells express
adhesion molecules which bind their ligand on BM stromal
cells, releasing angiogenic and bone-resorbing factors, which
disrupt the normal homeostasis of BM microenvironment
causing bone metastasis (Figure 1) [20, 21]. For instance,
vascular endothelial molecule-1 (VCAM-1) is expressed in
breast cancer and binds 𝛼4𝛽7 and 𝛼4𝛽1 (VLA-4) integrins on
OC precursors with high affinity, causing osteoclastogenesis.
𝛼4 or VCAM-1 blocking antibodies effectively inhibit bone
metastasis [22]. 𝛼V𝛽3 is another integrin expressed by breast
cancer cells [23], which is particularly important for OC
adhesion to bone [23]. CD44 is a molecule highly expressed
by breast cancer cells, which promotes invasion and adhesion
to BM [24]. Moreover, CD44 is also expressed by breast
cancer stem cells which can lie in a dormant state in the BM
[25] and then directly induce bone metastasis [26].
CXCL12, expressed by OBs and endothelial cells in BM,
and its receptors CXCR-4 regulate cell migration and bone
metastasis from prostate cancer [27, 28]. When cancer cells
reach the bone microenvironment, they induce the release
of different factors enmeshed in the bone matrix, such as
bone morphogenetic proteins (BMPs), transforming growth
factor-𝛽 (TGF-𝛽), insulin-like growth factor (IGF), and
fibroblast growth factor (FGF) as well as others that stimulate
the growth of metastatic tumor cells (Figure 1) [29]. The last,
in turn, secretes prostaglandins, PTH, PTH-related peptide,
activated vitamin D, interleukin-6 (IL-6), and tumor necrosis
factor (TNF), leading to an increase in receptor activator of
nuclear factor NF-kB ligand (RANKL) expression on OBs
and BM stromal cells [4], which stimulates the OC number
and survival and activity (Figure 1). Interestingly, prostate
and breast cancer cells respond to these factors activating dif-
ferent OB transcription factors [30, 31]; thus cancer cells can
differentiate into an osteoblastic bone-forming phenotype.
Journal of Immunology Research 3
This phenomenon is called osteomimicry and it has been
observed in bone metastatic prostate and breast cancer cell
lines [32–34].
Progenitors and mature cells in the BM frequently
expressed the receptor Notch [35], whereas the Notch ligand
Jagged is overexpressed by bone metastatic tumor cells [36].
Thus, cancer cells directly activate osteolysis through the
Notch-Jagged interactions in the BM. In particular, Jagged1,
which is a downstream mediator of the prometastatic TGF-
𝛽, directly activates OC differentiation and promotes tumor
growth stimulating IL-6 production by OBs [37].
3. Bone and Immune System Cross Talk
Bone and immune and hematopoietic systems are tightly
linked since bone cells and hematopoietic cells are in deep
physical contact, are reciprocally regulated, are intercon-
nected in their function, and share several common pathways
[38]. Indeed, bone cells express surface molecules regulating
the expansion ofHSCs fromwhich all cells of themammalian
immune system derive, whereas many immunoregulatory
cytokines directly act on bone cells [39, 40]. OBs and OCs
both affect the maintenance and the mobilization of HSCs
[13, 14]. OBs control the proliferation of hematopoietic pro-
genitors [41] and support commitment and differentiation of
all stages of B cell development. Indeed in vitro production of
B cell precursors from progenitors required contact with OBs
and expression of CXCL12 and interleukin-7 (IL-7), which
was induced by PTH [13, 42]. Moreover, OC precursors, T,
B, and NK cells originate from the same stem cell; thus, some
of the receptors and ligands that mediate the immune process
also regulate the maturation of OC precursors and the ability
of OCs to degrade bone. Circulating OC precursors are a
reservoir of the pre-OC pool in the BM, but they are also
an abundant source of pre-OCs that can be recruited into
bone or joint tissue in response to reparative or pathological
signals.
RANKL, its receptor RANK, and the natural decoy recep-
tor osteoprotegerin (OPG) [43] form a crucial molecular
link between the immune system and bone [44]. The mem-
brane RANKL is expressed by OBs/stromal cells; the soluble
RANKL was originally cloned from T cells [45, 46], but it is
also expressed by B cells [47], whereas the receptor RANK
is expressed by DCs, monocytes, macrophages, and tumor
cells [44, 48]. Activated T cells produce RANKL, which
directly regulates osteoclastogenesis and bone remodelling,
explaining why different pathological conditions, such as
cancer, result in systemic and local bone loss. The RANKL to
OPG ratio in serum is a determinant factor for OC activation
at bone level: a higher serumRANKL toOPG ratio is an index
for upregulation of osteoclastogenesis [49].
Many immune factors, including costimulatory receptors
and cytokines such as interferon-𝛾 (IFN-𝛾) and TNF regulate
bone cell development, bone turnover, and pathogenesis of
bone diseases [50]. The role of IFN-𝛾 in osteoclastogenesis is
controversial; indeed, in studies conducted in vitro [51] and in
vivo, in animal model, it shows an antiosteoclastogenic effect
[52], whereas, in humans, IFN-𝛾 increases in presence of bone
loss due to oestrogen deficiency and rheumatoid arthritis
[53, 54]. IFN-𝛾 influences osteoclastogenesis directly by
blockingOC formation through inhibition of OCmaturation
[55] and indirectly by stimulating T cell activation with a
consequent increase of proosteoclastogenic factors [56].
3.1. The Interactions between T Cells and Osteoclast Precursors
Regulate Bone Resorption in Bone Metastasis. A direct regu-
lation of bone resorption by T cell has been widely described
for bone metastasis by both solid tumors and multiple
myeloma (MM) [57, 58]. Indeed, studies on peripheral blood
mononuclear cells (PBMCs), isolated from patients affected
by breast, prostate, and lung cancer with bone metastases,
demonstrated an increase of circulating OC precursors in
these patients compared to patients without bone metastases
and healthy controls [58, 59]. In bonemetastatic patients, OC
precursors differentiate into mature OCs in vitro in presence
of T cells without adding M-CSF and RANKL, but T cell
depletion results in the absence of OC formation without
exogenous stimulation [58].
Another important mediator of the interactions between
T and bone cells is IL-7, a cytokine produced by stromal
cells and by cells at inflammatory site, with different effects
on hematopoietic and immunologic systems [60]. The main
function of IL-7 is the control of B and T lymphopoiesis
[61], but it is also important for the tumor process [62]
and the correct bone homeostasis [63, 64]. According to the
model considered, IL-7 displays either inhibitory or activator
effects on OCs [63, 65]. Some studies demonstrated that IL-7,
produced by T cells, promotes osteoclastogenesis by upregu-
lating T cell-derived cytokines, such as RANKL and TNF𝛼
[66–68], and that its production is increased by oestrogen
deficiency [69]. Furthermore, in bone metastatic patients,
IL-7 serum levels were significantly higher than those in
nonbone metastatic patients and in healthy controls [59, 68,
70]. This increase of serum IL-7 is at least in part dependent
on IL-7 production by tumor cells as demonstrated in a
human-in-mice model of bone metastasis from lung cancer
[71]. All these data confirm the T cell modulatory activity
on OCs. Nevertheless, also OCs affect T cell activity, because
they present antigenic peptides to T cells and induce FoxP3
expression in CD8 T cells, which regulate an inappropri-
ate activation of the immune response [72]. The cellular
responses in cell-to-cell interactions between T cells and
OCs are regulated through reciprocal CD137/CD137L and
RANK/RANKL interactions [73]. CD137 is a costimulatory
member of the TNF receptor induced by T cell receptor
activation. Its ligand CD137L is expressed on OC precur-
sors: in vitro CD137L ligation suppresses osteoclastogenesis
through the inhibition of OCs precursor fusion. On the other
hand, RANKL expressed on T cells binds to RANK on OCs,
producing a reverse signal in T cells able to enhance apoptosis
[73].
3.2. T Cells Regulate Tumor Growth in Bone. Many data
suggest that T cells can regulate tumor growth in bone also
independently from their interaction with bone cells. Indeed,
memory T cells have been found in the BM of breast cancer
patients suggesting their role in cancer immune surveillance
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[74]. Moreover, the RANKL-RANK interaction between
CD4 T cells and breast cancer cells promotes invasion,
dissemination, and metastasis formation in an animal model
[75]. Some antibone metastatic therapies show immunomo-
dulatory effects; for instance, the blockade of TGF-𝛽 at meta-
static sites may locally activate an antitumor T cell response,
because, normally, TGF-𝛽, released in BM by OC activity,
inhibits T cell proliferation [76].
Zoledronic acid, an antiresorptive agent, can activate
cytotoxic 𝛾/𝛿-T cells and inhibit populations of myeloid
derived cells with T cell suppressor capabilities [77]. Modu-
lation of antitumor T cell responses alters tumor growth in
bone. Indeed, by usingmicemodels Lyn−/−, which havemore
OCs and a hyperactive myeloid population with an increased
T cell responses, Zhang et al. reported a reduced tumor
growth in bone despite enhanced osteolysis [78]. Lyn is a
member of the Src family tyrosine kinases, which inhibits OC
differentiation by downregulating PLC𝛾2 activation, which
regulates the OC formation and function [79]. PLC𝛾2−/−
mice have an increased bone tumor burdendespite protection
from bone loss, because they have dysfunctional OCs and
impaired T cell activation mediated by DCs. Importantly,
injection of antigen-specific wild-type cytotoxic CD8 T cells
in both these mice models reduces the growth of tumor cells
in the bone, regardless of OC functionality. According to
these data, a condition of immune deficiency can interfere
with the antitumor effects of OC blockade [78]. In particular,
cytotoxic CD8 T cells seem to be critical regulators of tumor
growth in bone, since their activation diminishes and their
depletion enhances bone metastases, even with zoledronic
acid.
3.3. Myeloid Derived Suppressor Cells Regulate Cancer Pro-
gression. Myeloid derived suppressor cells are a heteroge-
neous population of immature myeloid cells identified by
the coexpression of Gr-1 and CD11b in mice and CD11b
and CD33 in humans [80–83]. MDSCs are significantly
overproduced in tumor-bearingmice and cancer patients and
they represent a prognostic indicator in various osteotropic
tumors including breast, lung and MM [84, 85]. Emerging
evidences suggest the importance of the MDSCs in driving
the progression of cancer disease by suppressing both the
innate and the adaptive immune response. Thus, MDSCs
exert their proneoplastic effects through the impairment
of T cell/antigen recognition, the release of small soluble
oxidizers, and depletion of essential amino acids from the
local extracellular environment [86–88]. Besides suppressing
CD4 and CD8 T cell populations, MDSCs promote the
activation and expansion of regulatory T cells (Treg) and thus
mediate immunosuppression.
Finally, all these mechanisms contribute to tumor pro-
gression and metastasis spreading to many organs, especially
to bone (Figure 1).
Bone metastases are associated with an increase in OC
activation and since MDSCs are progenitors of the OC pre-
cursors, it is not surprising that they are found to be largely
increased in bonemetastatic patients. Strikingly, Sawant et al.
confirmed that MDSCs isolated from tumor-bone microen-
vironment can differentiate into mature and functional OCs
in vitro and in vivo in a mouse model of breast cancer bone
metastases [89]. MDSCs from mice bearing bone metastases
also induce osteolysis in syngenic animals, indicating that
these cells are primed as OC progenitors and the bone
microenvironment triggers their activation in functional
OCs. It has been also suggested that cancer cells release
different soluble factors in the bone, which promotesMDSCs
to differentiate into OCs.Thus, breast cancer cells can secrete
CCL2, CCL5, or osteopontin which promotes the expression
of cathepsin K andmatrix metalloproteinase 9 (MMP9), thus
enhancing OC functions [90]. On the other hand, MDSC
expresses several proosteoclastogenic factors as CCR2, the
receptor of CCL2, showing the responsiveness of these cells
to the chemokine. Similarly, in the MMmodel, Zhuang et al.
discovered that tumor induced MDSCs were responsible to
induce osteolytic lesions by acting as OC precursors [91].
Additionally, only MDSCs isolated from bone are capable of
becoming active OCs, suggesting the importance of the bone
microenvironment in driving OC maturation.
Despite the critical role for OCs in the establishment of
bone metastatic vicious cycle, the PLC𝛾2−/− mouse model,
bearing severe OC defects, suggests thatMDSCs can enhance
tumor growth in bone independently of their ability to differ-
entiate into OCs [78]. Interestingly, the increased PLC𝛾2−/−
tumor growth was the result of a higher MDSCs accumu-
lation in secondary lymphoid organs, leading to a strong
inhibition of the antitumor T cell response (Figure 1). Despite
the importance of MDSCs expansion as a crucial event
in the pathogenesis of tumor progression, little is known
about the mechanisms leading to this process. Capietto et
al. have recently shown 𝛽-catenin as a crucial modulator
of MDSC accumulation in response to tumor [92]. The
downregulation of 𝛽-catenin signaling in MDSC promotes
their expansion and consequently increases tumor growth
in both mice and humans. On the contrary, expression of a
constitutively activate form of 𝛽-catenin in mice decreased
the number of MDSCs and tumor growth. Importantly, the
downregulation of 𝛽-catenin can also occur in MDSCs from
WT mice during tumor dissemination to bone, indicating
that 𝛽-catenin pathway modulates MDSC expansion in both
primary and metastatic solid tumors.
4. Conclusions
The rapidly developing field of osteoimmunology shows the
importance of the deep interconnection between skeletal and
immune system. This relationship results in the generation
of several cellular pathways, which provides the discovery
of new potential targets for the prevention and treatment of
bone metastasis.
The bone marrow represents an active and hospitable
microenvironment, allowing multiple cell interactions which
are critical in the pathogenesis of tumor progression. Thus,
additional studies to elucidate new mechanisms promoting
the accumulation of bone marrow derived cells such as
MDSCs are mandatory to address the critical steps of tumor
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progression in bone. The design of new drugs must consider
the potential effects on both immune system and bone; thus
further investigations to understand the osteoimmune system
are even more important.
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